Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Heritage Bio Labs

Research Library

Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.

Browse by productGeneral topics

Find articles

Matching articles

Showing 13–24 of 76 articles · Understand the science

Clear search and filters

  • Understand the science

    How the 2026 compounding policy treats single ingredients

    BPC-157 is a synthetic 15-amino-acid peptide, and TB-500 is defined in an October 2026 U.S. policy as an acetylated seven-amino-acid fragment related to thymosin beta-4. The policy gives each substance its own identity and addresses a specific question about compounding under federal law.

    BPC-157 / TB-5002 sources (2026)

  • Understand the science

    How REDEFINE 1 researchers studied blood pressure

    Cagrilintide is an investigational amylin-based peptide studied alone and as part of CagriSema with semaglutide. An analysis published in December 2025 examined blood pressure readings collected in the REDEFINE 1 weight-management trial.

    Cagrilintide3 sources (2023–2026)

  • Understand the science

    What frozen receptor images show about cagrilintide

    Cagrilintide is a long-acting peptide based on amylin, a hormone associated with signals after eating. For the specific question of how the peptide sits in its receptors, the older direct evidence comes from a 2025 study that visualized cagrilintide bound to several versions of the receptor family.

    Cagrilintide1 source (2025)

  • Understand the science

    How a change near one end can affect peptide breakdown

    CJC-1295 No DAC generally denotes Mod GRF (1–29), a growth hormone–releasing hormone (GHRH) fragment with four substitutions and no albumin-binding attachment. One of those substitutions helps frame a question about how researchers study peptide stability.

    CJC-1295 No DAC2 sources (1989, 2024)

  • Understand the science

    How a laboratory identified a no-DAC sequence in an unknown sample

    CJC-1295 No DAC commonly names Mod GRF (1–29), an engineered version of the first 29 amino acids of growth hormone–releasing hormone (GHRH). How can a laboratory establish that an unknown preparation contains a peptide consistent with that description?

    CJC-1295 No DAC2 sources (2010, 2024)

  • Understand the science

    From a growth hormone signal to an outcome in people

    CJC-1295 No DAC generally refers to Mod GRF (1–29), a 29-residue analogue designed around the natural signal for growth hormone release. An important research question is how a hormone measurement could be connected to an outcome that matters to people with growth hormone deficiency.

    CJC-1295 No DAC1 source (2024)

  • Understand the science

    How long did growth hormone and IGF-1 change in early human trials?

    CJC-1295 With DAC is an investigational form of a growth hormone–releasing hormone (GHRH) analogue. Its attached drug affinity complex (DAC) allows it to bind to blood proteins. Early studies asked how long the circulating peptide and its effects could be measured in healthy adults.

    CJC-1295 With DAC2 sources (2005, 2024)

  • Understand the science

    What the original albumin-binding experiments established

    CJC-1295 With DAC is an engineered form of growth hormone–releasing factor (GRF), also called growth hormone–releasing hormone. Its drug affinity complex (DAC) was designed to react with the blood protein albumin. The original 2005 development study provides older direct evidence for that design.

    CJC-1295 With DAC2 sources (2005, 2026)

  • Understand the science

    Following two signals inside cultured pituitary cells

    CJC-1295 (No DAC) / GHRP-2 lists two peptides expected to enter the growth hormone system at different points. The no-DAC label commonly means modified GHRH(1–29). GHRP-2 is a synthetic peptide that stimulates the growth hormone secretagogue pathway.

    CJC-1295 (No DAC) / GHRP-22 sources (1998, 2024)

  • Understand the science

    How structural studies show two different receptor targets

    CJC-1295 (No DAC) / GHRP-6 names a modified growth hormone–releasing hormone (GHRH) fragment and a separate synthetic peptide that activates the ghrelin receptor. Structural research helps clarify what it means to give those two signals different receptor targets.

    CJC-1295 (No DAC) / GHRP-63 sources (2020–2024)

  • Understand the science

    What happened when researchers blocked the body's own releasing signal?

    CJC-1295 (No DAC) / GHRP-6 names a modified 29-residue analogue of growth hormone–releasing hormone (GHRH) plus a six-residue peptide that stimulates the ghrelin receptor. Does the growth hormone response to GHRP-6 depend on the body's existing GHRH activity?

    CJC-1295 (No DAC) / GHRP-62 sources (1998, 2024)

  • Understand the science

    What a single-compound time course can show about a proposed pairing

    CJC-1295 (No DAC) / Ipamorelin names a modified growth hormone–releasing hormone fragment and ipamorelin, a five-residue ghrelin-receptor agonist. Would the timing of ipamorelin's effect by itself predict the timing of the two-peptide response?

    CJC-1295 (No DAC) / Ipamorelin2 sources (1999, 2024)

Browse by product

General topics

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Library index (JSON)